CLOBETASOL PROPIONATE (EMOLLIENT)
Clinical safety rating: safe
No significant drug interactions Systemic absorption can cause reversible HPA axis suppression with potential for glucocorticosteroid insufficiency.
Clobetasol propionate is a potent corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2 activity, decreased arachidonic acid release, and reduced synthesis of inflammatory mediators such as prostaglandins and leukotrienes, thereby exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Metabolized primarily in the liver via ester hydrolysis to inactive metabolites; excreted renally and in feces. |
| Excretion | Renal (primarily as metabolites) and fecal. After topical application, <5% of the dose is excreted unchanged in urine; the majority is metabolized hepatically and excreted via bile into feces. |
| Half-life | Terminal elimination half-life is approximately 5.6 hours (range 3.0–10.5 h) following topical application. Systemic absorption is minimal, but this half-life reflects clearance of absorbed drug. |
| Protein binding | Approximately 96–99% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Systemic Vd is not well characterized due to extensive tissue binding and lipophilicity; estimated to be 45–120 L (approximately 0.6–1.7 L/kg) for absorbed drug, indicating extensive extravascular distribution. |
| Bioavailability | Topical: Systemic bioavailability is <5% through intact skin; increases to up to 20–30% with occluded or damaged skin. Not available for oral or parenteral routes in this formulation. |
| Onset of Action | Topical: Improvement in inflammation and pruritus may be noted within 2–3 days of twice-daily application, though full effect may take up to 1–2 weeks. |
| Duration of Action | Topical: Duration of action after a single application is approximately 12–24 hours, supporting twice-daily dosing. For scalp formulations, effect may persist for 24–48 hours after application. |
| Molecular Weight | 466.97 |
Apply topically to affected areas once or twice daily. Maximum 50 g/week for adults. Duration limited to 2 weeks continuous use.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required. Systemic absorption minimal. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment due to potential for increased systemic absorption. |
| Pediatric use | Apply sparingly once daily for no more than 2 weeks. Limit to 15 g/week. Not recommended for children under 1 year. |
| Geriatric use | Use lowest effective dose due to thinner skin and increased potential for systemic absorption. Avoid long-term use. |
| 1st trimester | Topical corticosteroids are generally avoided during first trimester unless benefit outweighs risk. Clobetasol propionate is a super-high potency corticosteroid; minimal systemic absorption occurs with topical use but high potency increases risk. Use only if clearly needed and for shortest duration. |
| 2nd trimester | Limited data; avoid prolonged use, large areas, or occluded sites. Use lowest effective potency. Topical corticosteroids have not been associated with significant teratogenic risk but high potency agents should be used cautiously. |
| 3rd trimester | Avoid high-potency corticosteroids in third trimester due to potential for fetal growth restriction and adrenal suppression. Use only if essential and for short-term, limited areas. |
Clinical note
No significant drug interactions Systemic absorption can cause reversible HPA axis suppression with potential for glucocorticosteroid insufficiency.
| FDA category | Animal |
| Placental transfer |
■ FDA Black Box Warning
Systemic absorption of topical corticosteroids, including clobetasol propionate, can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and unmask latent diabetes. Use in children or on large areas, occluded areas, or prolonged periods may increase systemic absorption.
| Common Effects | Skin atrophy |
| Serious Effects |
Hypersensitivity to clobetasol propionate or any component of the formulationUntreated bacterial, fungal, viral, or parasitic infections at application siteRosaceaPerioral dermatitisAcne vulgaris
| Precautions | Avoid use on face, groin, axillae, or intertriginous areas unless directed by physician. Use with caution in patients with impaired circulation. Prolonged use may lead to skin atrophy, striae, telangiectasias. Discontinue if irritation develops. Not for ophthalmic or oral use. |
| Food/Dietary |
Loading safety data…
| Limited data; based on molecular weight and lipophilicity, minimal systemic absorption from topical application results in negligible placental transfer. However, significant absorption (e.g., excessive use) may allow transfer. |
| Breastfeeding | Topical application to limited areas is unlikely to result in significant systemic absorption. However, use on large areas, broken skin, or under occlusion may increase exposure. Avoid application to breasts to prevent infant ingestion. Use lowest potency and shortest duration possible. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Topical corticosteroids are generally considered low risk for teratogenicity when used in small amounts and for short durations. However, high potency corticosteroids like clobetasol propionate should be used with caution during pregnancy, especially in the first trimester. Case reports and small studies suggest a potential increased risk of orofacial clefts with first trimester use of systemic corticosteroids, but data for topical application are limited and do not confirm a significant risk. Application to large areas, occluded sites, or prolonged use may increase systemic absorption. Overall, the risk likely minimal with appropriate use. |
| Fetal Monitoring | No specific maternal or fetal monitoring is routinely required for topical clobetasol use during pregnancy. However, if used extensively, especially on compromised skin or under occlusion, monitoring for signs of systemic corticosteroid effects (e.g., hypothalamic-pituitary-adrenal axis suppression) may be considered. Fetal growth and development monitoring are not specifically indicated based on topical use. |
| Fertility Effects | Data are insufficient to determine effects on fertility. Systemic corticosteroids may affect menstrual cycle or sperm quality in high doses, but topical application at recommended doses is unlikely to cause significant reproductive toxicity. No specific fertility studies with topical clobetasol propionate have been reported. |
| No known food interactions. No dietary restrictions required. |
| Clinical Pearls | Clobetasol propionate emollient is a super-high-potency topical corticosteroid. Do not use for more than 2 consecutive weeks, and limit to ≤50 g/week due to risk of HPA axis suppression. Avoid application to face, groin, or axillae. Use with caution in children and elderly. Oclusive therapy may enhance absorption but increases systemic exposure. |
| Patient Advice | Apply a thin layer to affected skin only, rubbing in gently. · Do not cover with bandages or dressings unless directed by a doctor. · Wash hands after application unless treating hands. · Do not use on face, underarms, or groin unless specifically instructed. · Do not use for more than 2 weeks continuously without reassessment. · Avoid contact with eyes and mucous membranes. · Report any signs of skin thinning, infection, or irritation. · Do not stop abruptly if used on large areas or for prolonged periods. |